Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01118494|
Recruitment Status : Unknown
Verified April 2010 by Fudan University.
Recruitment status was: Recruiting
First Posted : May 6, 2010
Last Update Posted : May 6, 2010
|Condition or disease|
|Chronic Kidney Disease Urinary Angiotensinogen|
- Screening: Select CKD(3-4) patients from outpatients, Urine routine examination and Renal B-mode ultrasonography and so on.
- Confirm: Sign consent with the patients who meet the inclusion criteria, then these patients are included in the study.
- Create patients records and complete related-inspections.
- Clinical follow-up: Follow-up once every six months, and we will record every patient's disease progress every time. Each follow-up, the patient needs to leave 5 ml blood samples and 20 ml of urine samples, used for the following study.
- Detection, Observation and Evaluation: Patients are divided into two groups according to AGT levels: higher than the normal group and the normal group. Observe the changes in eGFR of different group. Statistics judge whether AGT can be as a early warning indicators of renal function decline.
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Study Start Date :||September 2009|
|Estimated Primary Completion Date :||February 2010|
|Estimated Study Completion Date :||June 2011|
People who have been diagnosed with CKD，and been in the stage of 3 or 4.
- Urinary AGT level [ Time Frame: 12 months ]Urinary AGT level can be an early bio-marker of intrarenal RAS activation and prewarning the deterioration of renal function.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01118494
|Contact: Yong Gu, firstname.lastname@example.org|
|Nephrology Department of Huashan Hospital||Recruiting|
|Shanghai, Shanghai, China, 200042|
|Contact: Yong Gu, Doctor 13916322128 email@example.com|